ClinicalTrials.gg
CompletedNCT05506540Updated Sep 19, 2024

A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects

A Phase 1 interventional study of ENN0403 1mg and ENN0403 4mg in Healthy, sponsored by EnnovaBio. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by EnnovaBio · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Feb 2021, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a FIH, randomized, double- blind, placebo-controlled, dose -escalation study to investigate the safety, tolerability, PK, and PD of ENN0403 after single and multiple oral dose administration in healthy adult subjects. The study will include 2 parts which will proceed in a parallel staggered manner: Part A, a single ascending dose (SAD) study and Part B, a multiple ascending dose (MAD) study.

Approximately 80 healthy adult subjects will be enrolled at a single site in Australia, in up to 6 cohorts in Part A (SAD study), including a Food Effect (FE) study, and up to 4 cohorts in Part B (MAD study). Part A is for the single dose use of IP, while Part B is once daily use for 14 consecutive days. Each cohort will include 8 subjects (6 receiving ENN0403 and 2 receiving placebo). Each subject will be enrolled in only 1 cohort and receive only one dose regimen in this study.

Dosing will be escalated in a sequential fashion, contingent on a review of safety, tolerability, and available PK data of the previous dose level by a Safety Review Committee (SRC). The proposed dose levels/ dosing frequency of ENN0403 may be adjusted over the course of the whole study and cohorts may be added or removed depending on the emerging safety, tolerability, and available PK data.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

EnnovaBio is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed .
  • 18 to 55 years old (inclusive).
  • of 18 to 30 kg/m2 (inclusive); body weight >50 to \<100 kg for male subjects or >45 to \<100 kg for female subjects.
  • Computerized (12-lead) recording without signs of pathology or showing no clinically relevant deviations as judged by the PI.
  • Test negative for COVID-19.
  • Test negative for , anti-HBc, anti- virus (HCV) antibodies, anti-human immuno deficiencyvirus () 1 and 2 antibodies, and tuberculosis.
  • Have a negative urine drug screen and a negative alcohol breath test.
  • Nonsmoker or occasional smoker and willingness to refrain from smoking during study.
  • Ability and willingness to abstain from alcohol during study.
  • not pregnant, not breastfeeding; apply methods for subjects.

Exclusion criteria

Exclusion Criteria:

  • History of hematological, renal, endocrine, pulmonary, gastrointestinal,cardiovascular, hepatic, psychiatric, neurologic, or allergic disease in the opinion of the Investigator within 12 months prior to Screening.
  • Any disease or take any medication that affects IP absorption, distribution, metabolism, and excretion.3. Family history of sudden death or of congenital prolongation of the or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval.
  • Presence of including hematological malignancies. Subjects with a history of basal cell or squamous cell carcinoma that has been treated with no evidence of recurrence within 3 years of Screening will be allowed for inclusion, as judged by the Investigator.
  • Any current active infections, including localized infections, or any recent history (within 1 week prior to IP administration) of active infections, cough or fever; or a history of recurrent or chronic infections.
  • In the 12-lead assessment, QTcF >450 ms for male subjects or >470 ms for female subjects.7. Estimated glomerular fltration rate \<90 mL /min (using the formula) at Screening.
  • or aspartate aminotransferase>1.5ULN.
  • Have received any (bacterial or viral) within 12 weeks prior to Screening or intend to receive a live vaccine during the study period or within 30 days after the last dose of the IP.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose, ENN0403 1 mg

    Single oral use of ENN0403 at dose level 1 mg, in fasted state.

    Drug: ENN0403 1mg

  • Experimental
    Single Ascending Dose, ENN0403 4 mg

    Single oral use of ENN0403 at dose level 4 mg, in fasted state.

    Drug: ENN0403 4mg

  • Experimental
    Single Ascending Dose, ENN0403 10 mg

    Single oral use of ENN0403 at dose level 10 mg, in fasted state.

    Drug: ENN0403 10mg

  • Experimental
    Single Ascending Dose, ENN0403 20 mg

    Single oral use of ENN0403 at dose level 20 mg, in fasted state.

    Drug: ENN0403 20mg

  • Experimental
    Single Ascending Dose, ENN0403 30 mg

    Single oral use of ENN0403 at dose level 30 mg, in fasted state.

    Drug: ENN0403 30mg

  • Experimental
    Single Ascending Dose, ENN0403 20 mg (Fed)

    Single oral use of ENN0403 at dose level 30 mg, after high calorie and high-fat breakfast meal.

    Drug: ENN0403 20mg (Fed)

  • Experimental
    Multiple Ascending Dose, ENN0403 6 mg

    ENN0403 capsules for oral administration, 6 mg QD X 14 Days

    Drug: ENN0403 6mg QD X 14 Days

  • Experimental
    Multiple Ascending Dose, ENN0403 12 mg

    ENN0403 capsules for oral administration, 12 mg QD X 14 Days

    Drug: ENN0403 12mg QD X 14 Days

  • Experimental
    Multiple Ascending Dose, ENN0403 20 mg

    ENN0403 capsules for oral administration, 20 mg QD X 14 Days

    Drug: ENN0403 20mg QD X 14 Days

  • Placebo comparator
    Single/Multiple Ascending Dose, placebo capsules for oral adminstration

    Placebo capsules for oral administration

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment emergent adverse events (TEAE) following ENN0403 administration

    Time frame: From first dose of ENN0403 administration till 7 days after last dose of ENN0403 administration.

Secondary outcomes

  1. Maximum Plasma Concentration [Cmax]

    Cmax is the maximum measured concentration of ENN0403 in plasma after oral administration

    Time frame: Single Ascending Dose (SAD) part: up to Day 4, 72 hours post dose; Multiple Ascending Dose (MAD) part: up to Day 17, 72 hours post last dose

  2. Area Under the Curve [AUC]

    AUC is the area under the concentration-time curve of ENN0403 in plasma after oral administration

    Time frame: Single Ascending Dose (SAD) part: up to Day 4, 72 hours post dose; Multiple Ascending Dose (MAD) part: up to Day 17, 72 hours post last dose

07

Study locations

1 site
  • CMAX Clinical Research Pty Ltd
    Adelaide, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in May 2022, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2022
First posted
Aug 18, 2022
StartActual
Feb 17, 2021
Primary completionActual
May 16, 2022
CompletionActual
May 16, 2022
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05506540
Lead sponsor
EnnovaBio
Responsible party
Sponsor
First posted
Aug 18, 2022
Start date
Feb 17, 2021
Primary completion
May 16, 2022
Completion
May 16, 2022
Last update
Sep 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ENN0403

Start the discussion